BioSpace News Archive

Aditx Therapeutics, Inc. (the “Company”) (Nasdaq: ADTX), a life sciences company developing technologies specifically focused on improving the health of the immune system through immune reprogramming and monitoring, today announced the pricing of its initial public offering of 1,226,668 units at an offering price of $9.00 per unit.

Lipidor AB (“Lipidor” or the “Company”) and its subsidiary Emollivet AB (“Emollivet”) have formalized the relationship by entering into a licence agreement that regulates the right to Lipidor’s patented AKVANO® technology

MYOS RENS Technology, Inc. (“MYOS”) (NASDAQ: MYOS), an advanced nutrition company and the owner of Fortetropin®, a proprietary bioactive composition that helps build lean muscle, and MedAvail, Inc. (“MedAvail”), a private, in-clinic telemedicine-enabled pharmacy organization that has developed and commercialized a proprietary robotic dispensing platform and home delivery operation focused on the Medicare Advantage market in the United States,

IMV Inc. announced that in order to maintain the remainder of its at-the-market facility announced on March 18, 2020 under its new Canadian base shelf prospectus, it re-entered into an equity distribution agreement dated June 30, 2020 with Piper Sandler & Co. pursuant to which the Company may from time to time sell through “at-the-market” offerings, with Piper Sandler acting as sales agent

The U.S. Food and Drug Administration continued to take action in the ongoing response to the COVID-19 pandemic

Liminal BioSciences Inc. (NASDAQ: LMNL) (TSX: LMNL) (“Liminal BioSciences” or the “Company”), a clinical-stage biopharmaceutical company, today provided a guidance update on the timing of certain expected key milestones for 2020.

InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN) (OTCQX:IMLFF), a clinical-stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (“CBN”), is pleased to announce, further to its press release dated June 19th, 2020,

CRISPR Therapeutics, a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, announced the pricing of an underwritten public offering of 6,428,572 common shares at a public offering price of $70.00 per share.

American Bio Medica Corporation (OTC PINK:ABMC) today announced financial results for the fourth quarter and year ended December 31, 2019.

Neutra Corp. (OTC PINK:NTRR) is busy moving its administrative offices to its newly opened manufacturing and production site in Katy.